We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cardiovascular Risk Biomarkers Found for JSLE Patients

By LabMedica International staff writers
Posted on 25 Jun 2019
Print article
Image: Lupus Erythematosus (LE) Cells are neutrophils that have engulfed lymphocyte nuclei coated with and denatured by antibody to nucleoprotein (Photo courtesy of Dr. Moustafa Abdou).
Image: Lupus Erythematosus (LE) Cells are neutrophils that have engulfed lymphocyte nuclei coated with and denatured by antibody to nucleoprotein (Photo courtesy of Dr. Moustafa Abdou).
Systemic lupus erythematosus is an autoimmune disease typically affecting women between the ages of 15 and 50, and symptoms flare up unpredictably. Approximately 20% of cases begin during childhood and in these patients the disease is suggested to be more severe.

Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune dysregulation, chronic inflammation and increased cardiovascular risk (CVR). Cardiovascular disease is the leading cause of mortality in JSLE not attributable to lupus flare. Symptoms of this diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.

A team of scientists working with the University College London (London, UK) to investigated dyslipidemia and CVR in a cohort of JSLE patients using in depth metabolomics and related this to clinical and immune cell profiles and to identify novel biomarkers to predict CVR in these patients. Metabolic biomarker analysis by Nuclear Magnetic Resonance (NMR) and in-depth immune cell phenotyping (30 subsets by flow cytometry) was performed on serum and peripheral blood mononuclear cells (PBMCs) respectively from a discovery cohort of 35 JSLE patients (median age 19 (14-25), 12 males, 23 females) compared with 39 age/sex matched healthy donors (HCs) (median age 18 (16-25), 17 males, 22 females).

The team reported that patient stratification by metabolomic profile using unbiased hierarchical clustering revealed three groups that each had a unique lipoprotein profile, immune cell phenotype and clinical presentation. Group-1 had decreased atheroprotective high-density lipoproteins (HDL) and increased atherogenic very low and low-density lipoproteins (VLDL/LDL). Group-2 had elevated HDL, but reduced VLDL/LDL indicating that these groups could be at high and low CVR respectively. Patients in Group-3 displayed an intermediate CVR but a pro-inflammatory immune cell profile.

Patients in Group-1 had a significant increase in plasmablasts and activated T-cells compared to HCs and had clinical features associated with increased disease activity. This metabolomic patient stratification was validated in a separate JSLE cohort. Importantly ApoB:A1 ratio was identified as a highly predictive biomarker distinguishing between JSLE patients in Group-1 and 2, indicating high and low CVR respectively. Finally, longitudinal analysis revealed that the ApoB:A1 ratio biomarker remained stable over time.

George A. Robinson, PhD, a senior research associate and co-author of the study, said, “Our study identifies ApoB:A1 ratio and metabolomic lipoprotein signatures as potential new biomarkers to predict cardiovascular risk in patients with juvenile-onset SLE. Patient stratification using these biomarkers could provide an opportunity for tailored disease treatments using lipid modification therapy and lifestyle interventions.” The study was presented at the Annual European Congress of Rheumatology held June 12-15, 2019, in Madrid, Spain.

Related Links:
University College London

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.